beta-Propiolactone (BPL) inactivates LAV/HTLV III, the retrovirus associated with acquired immune deficiency syndrome (AIDS). Addition to specimens from patients with suspected AIDS or antibodies to LAV/HTLV III could reduce any occupational risk to laboratory staff. This study demonstrates that BPL treatment does not significantly affect the immunological analyses commonly required on these patients, namely measurements of serum immunoglobulins, complement components C3 and C4 and other seru...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Effect of beta-propiolactone--an inhibitor of HTLV III/LAV activity--on immunological analyses.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record